Immedica to buy Marinus Pharmaceuticals for $151m
The deal is anticipated to expand Immedica’s rare disease portfolio by adding ZTALMY oral suspension, CV.
deal
Investors optimistic about continued biotech and medtech IPO resurgence in 2025
AlloVir and Kalaris enter merger to advance retinal disease therapies
Sanofi’s $17bn sale of Opella to US investors advances following government deal
Sanofi signs radioligand therapy licensing deal for rare cancers
UCB to divest China neurology and allergy business for $680m
Rafael Holdings and Cyclo Therapeutics enter merger deal
VION Biosciences acquires Echelon Biosciences
